Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 15;12(2):661-680.
eCollection 2022.

Diagnostic and therapeutic biomarkers in colorectal cancer: a review

Jéssica Vieira de Assis  1 , Lucélia Antunes Coutinho  1 , Ifeoluwa Temitayo Oyeyemi  2 , Oyetunde Timothy Oyeyemi  1   2 , Rafaella Fortini E Queiroz Grenfell  1   3
Affiliations
Review

Diagnostic and therapeutic biomarkers in colorectal cancer: a review

Jéssica Vieira de Assis et al. Am J Cancer Res. .

Abstract

Colorectal cancer (CRC) is a public health concern and the second most common type of cancer among men and women causing a significant mortality. Biomarkers closely linked to the disease morbidity could holds potential as diagnostic and/or prognostic biomarker for the disease. This review provides an overview of recent advances in the search for colorectal cancer biomarkers through genomics and proteomics according to clinical function and application. Specifically, a number of biomarkers were identified and discussed. Emphasis was placed on their clinical applications relative to the diagnosis and prognosis of CRC. The discovery of more sensitive and specific markers for CRC is an urgent need, and the study of molecular targets is extremely important in this process, as they will allow for a better understanding of colorectal carcinogenesis, identification and validation of potential genetic signatures.

Keywords: Biomarkers; colorectal cancer; management; prognosis.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Hauptman N, Jevšinek Skok D, Spasovska E, Boštjančič E, Glavač D. Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer. BMC Med Genomics. 2019;12:54. - PMC - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018;144:1941–1953. - PubMed
    1. Chen E, Yang F, He H, Li Q, Zhang W, Xing J, Jiang J, Wang H, Zao X, Liu R, Lei L, Dong J, Pei Y, Yang Y, Pan J, Zhang P, Liu S, Du L, Zeng Y, Yang J. Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study. Mol Cancer. 2018;17:176. - PMC - PubMed
    1. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2017;24:1062–1072. - PMC - PubMed
    1. Kieler M, Unseld M, Bianconi D, Waneck F, Mader R, Wrba F, Fuereder T, Marosi C, Raderer M, Staber P, Berger W, Sibilia M, Polterauer S, Müllauer L, Preusser M, Zielinski CC, Prager GW. Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. ESMO Open. 2019;4:e000538. - PMC - PubMed

LinkOut - more resources